Document is current
Any future updates will be listed below
-
Authors
Eichner, Adina https://orcid.org/0000-0002-3942-9192
Mrestani, Yahya
Hukauf, Martin
Wohlrab, Johannes
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 25 June 2024
First Online: 12 July 2024
Declarations
:
: The authors declare that no interests or support of the manufactures of Ecural<sup>®</sup> ointment and Momecutan<sup>®</sup> ointment have influenced the present work. Both drugs were chosen because of their availability, experience in analytics and robustness. Adina Eichner and Yahya Mrestani have no conflict of interests. Martin Hukauf declares that StatConsult has received fees for carrying out the statistical analyses. Johannes Wohlrab declares that he has received honoraria for consulting and/or lectures, and/or sponsoring for scientific projects and/or clinical studies from the following companies in the last 5 years: Abbott, Abbvie, Actelion, Allergika, Almirall, Aristo, Apogee, Astellas, BayPharma, Beiersdorf, Biogen, BMS, Boehringer Ingelheim, Celltrion, Dermapharm, Evolva, Galderma, GSK, Helm, Hexal, Infectopharm, Incyte, Janssen-Cilag, Johnson & Johnson, Klinge, Leo, Lilly, L‘Oréal, Medac, Medice, Mibe, MSD, Mylan, Novartis, Pierre Fabre, Pfizer, Rigi, Sanofi, Skinomics, UCB, Viatris, Wolff.
: The present non-clinical investigations study is not a clinical trial. No patients were treated, but pharmacokinetic studies were carried out on commercially purchased anonymous skin samples (Biopredic International, Saint Grégoire, France); (Statutes of the Ethics Committee of the Medical Faculty of Martin Luther University Halle-Wittenberg, from 21 September 2020).
